Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
248 hedge funds and large institutions have $4.71B invested in Sage Therapeutics in 2018 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 91 increasing their positions, 88 reducing their positions, and 58 closing their positions.
38% more call options, than puts
Call options by funds: $129M | Put options by funds: $93.6M
1.08% more ownership
Funds ownership: 105.04% → 106.12% (+1.1%)
3% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 88
9% less funds holding
Funds holding: 274 → 248 (-26)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
32% less capital invested
Capital invested by funds: $6.93B → $4.71B (-$2.22B)
45% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$57.9M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$50.6M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$34.8M |
| 4 |
Bank of New York Mellon
New York
|
+$32.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$30.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$80.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$49.6M |
| 3 |
BlackRock
New York
|
-$35M |
| 4 |
Millennium Management
New York
|
-$26.3M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$25.7M |
SAGE Hedge Fund Activity: Q4 2018 in Review
248 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2018, worth a combined $4.71B — down 32% from $6.93B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of SAGE and 32 opened new positions — a net loss of 26 holders — while 88 trimmed existing stakes and 91 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $57.9M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $80.2M sold.
- 248 institutional investors held Sage Therapeutics (SAGE) as of Q4 2018, down from 274 in Q3 2018.
- Funds reported $4.71B of Sage Therapeutics stock for Q4 2018, down 32% quarter-over-quarter.
- 32 funds opened new Sage Therapeutics positions in Q4 2018 and 58 closed out, a net change of -26 holders.
- The largest Sage Therapeutics buyer in Q4 2018 was PFM Health Sciences, an estimated $57.9M added.
- The largest Sage Therapeutics seller in Q4 2018 was Baker Bros. Advisors, an estimated $80.2M sold.
Based on aggregated 13F filings for Q4 2018.